Case Study

Against All Odds: Phase III On A Breakthrough Therapy In Lupus Nephritis

Source: Worldwide Clinical Trials
Lupus Research Alliance Enhances Clinical Trials for Patients

In the face of challenges both predictable and unforeseen, Worldwide Clinical Trials brought our sponsor’s first FDA-approved oral therapy for lupus nephritis (LN) across the finish line on time.

Sponsor Challenges:

Recruitment: Experienced Sites with Inexperienced Patients

Patients at sites with significant experience with LN trials are typically already participating in a study. This study required sites familiar with LN clinical trials with clinically qualifying patients not already participating in LN studies.

Clinical: Unpredictable Medical Events

Within this study, strict protocol adherence would be a challenge. The investigational product was to be administered at the start of a proteinuria flare, so patients needed to recognize symptoms indicating when to visit the site.

Find out more in the available case study.

VIEW THE CASE STUDY!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader